BerandaTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Tutup sebelumnya
$3,72
Rentang hari
$3,62 - $3,76
Rentang tahun
$3,03 - $14,80
Kapitalisasi pasar
3,44Â jt USD
Volume Rata-Rata
28,06Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 666,00Â rb | -53,88% |
Laba bersih | -790,00Â rb | 59,90% |
Margin laba bersih | — | — |
Penghasilan per saham | — | — |
EBITDA | -666,00Â rb | 65,46% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,83Â jt | -58,12% |
Total aset | 2,92Â jt | -63,85% |
Total liabilitas | 483,00Â rb | -66,55% |
Total ekuitas | 2,44 jt | — |
Saham yang beredar | 914,23 rb | — |
Harga terhadap nilai buku | 1,39 | — |
Tingkat pengembalian aset | -51,03% | — |
Tingkat pengembalian modal | -58,72% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -790,00Â rb | 59,90% |
Kas dari operasi | -506,00Â rb | 77,47% |
Kas dari investasi | — | — |
Kas dari pembiayaan | -62,00Â rb | -115,27% |
Perubahan kas bersih | -568,00Â rb | 57,49% |
Arus kas bebas | -193,25Â rb | 80,89% |
Tentang
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Didirikan
1991
Kantor pusat
Situs
Karyawan
4
